Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Public ClinicalTrials.gov record NCT02798406. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD
Study identification
- NCT ID
- NCT02798406
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2016 (Actual)
- Primary completion
- Mar 17, 2021 (Actual)
- Completion
- Jun 30, 2021 (Actual)
- Last update posted
- Jul 15, 2021
2016 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences (UAMS) | Little Rock | Arkansas | 72205 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Minnesota Neurosurgery | Minneapolis | Minnesota | 55455 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Weill-Cornell Medicine New York-Presbyterian | New York | New York | 10065 | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27514 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Ohio State University James Cancer Center | Columbus | Ohio | 43210 | — |
| Lehigh Valley Health Network | Allentown | Pennsylvania | 18103 | — |
| Texas Oncology Austin-Midtown | Austin | Texas | 78705 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02798406, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02798406 live on ClinicalTrials.gov.